NCT00567697已完成3 期
A Randomized Study Comparing the Safty Anf Efficacy of Ranibizumab (Lucentis®) to Sham in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO
Aleris Helse4 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2007年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 4
- 主要终点
- The primary efficacy outcome measure is the mean change from baseline in BCVA score
研究概览
简要总结
A prospective multicenter study comparing patients with CRVO amd secondary macular edema treated with ranibizumab versus sham. Safety and efficacy will be evaluated. Patients will be randomized in a 1:1 ratio to one of the two arms. 32 patients, 6 months follow up. There will be monthly visits with injection the first three months and subsequently new injection if present edema.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female ≥ 50 years
- •Patients who have findings consistent with CRVO
- •Patients who have a history of decreased visual acuity ≤ 6 months
- •Patients who have a best corrected visual acuity (BCVA) letter score in the study eye of ≤ 73 (4 m distance) or ≥ 6 (1 m distance) using an ETDRS chart
- •Patients who have a macular edema verified by OCT
- •Patients who have macular edema in the study eye with the following characteristics as determined by fluorescein angiography:
- •secondary to non-iscemic CRVO defined as non-perfusion < 10 DA OR
- •secondary to ischemic CRVO defined as non-perfusion > 10 DA
- •Willing and able to give written informed consent and who are willing and able to comply with study procedures
- •Ability to cooperate with photo and OCT examinations
排除标准
- •Neovascularisations in the study eye at baseline
- •Previous treatment with or participation in a clinical trial (for either eye) involving anti-angiogenics drugs
- •Use of other investigational drugs
- •Prior treatment in the study eye with verteporfin, external-beam radiation therapy, subfoveal laser photocoagulation, vitrectomy, or transpupillary thermotherapy.
- •History of submacular surgery in the study eye, glaucoma filtration, corneal transplantation surgery
- •Previous or current intravitreal or sub-Tenon drug delivery in the study eye
- •Laserphotocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding Baseline
- •Extracapsular extraction of cataract with phacoemulcification within three months preceding Baseline, or a history of post-complications within the last 12 months preceding Baseline in the study eye (uveitis, cyclitis etc)
- •History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication)
- •Previous violation of the posterior capsule in the study eye unless it occurred as a result of YAG laser posterior capsulotomy in assosiation with prior, posterior chamber lens implantation
- •Afakia with absence of the posterior capsule in the study eye
- •Active intraocular inflammation in the study eye
- •Any active infection involving the ocular adnexa including infectious conjunctivitis, keratitis, scleritis, endophthalmitis, as well as ideopathic or autoimmune-associated uveitis in either eye
- •Vitreous hemorrhage or history og rhegmatogenous retinal detachment or macular hole in the study eye
- •Any current intraocular condition in the study eye (cataract or diabetic retinopathia) that in the opinion of the investigator, could either require medical or surgical intervention during the study period for the next 6 months
- •Ocular condition that requires chronic concomitant therapy with systemic or topical ocular corticosteroids.
- •Current treatment for active systemic infection.
- •Current use or likely need for systemic medications known to be toxic to the lens, retina or optic nerve.
- •History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or might affect interpretation of the results of the study or render the subject at high risk for treatment complications
- •History of hypersensitivity or allergy to fluorescein
- •Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed
- •Pregnant or nursing (lactating) women
- •Pre-menopausal women of child-bearing potential not using adequate contraception.
- •History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrance or metastases.
研究组 & 干预措施
A
Active Comparator
0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection
干预措施: ranibizumab (Drug)
B
Sham Comparator
干预措施: ranibizumab (Drug)
结局指标
主要结局
The primary efficacy outcome measure is the mean change from baseline in BCVA score
时间窗: 6 months
次要结局
- Mean change from baseline in BCVA score, central foveal thickness and in the NEI VFQ-25 near activities subscale.(6 months)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSCytomegalovirus RetinitisHIV InfectionsNCT00002330Roche Global Development280
已完成
3 期
Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry EyeDry Eye DiseaseNCT06323395Jadran Galenski laboratorij d.d.64
Unknown
3 期
Study on Prevention and Treatment of Dry Eye in Patients Using Glaucoma DropsMGD-Meibomian Gland DysfunctionDry EyeNCT03515187Shenzhen Hospital of Southern Medical University160
已完成
不适用
A Comparison of Hydrogel Dressings and Ocular Lubricants in the Prevention on Corneal Damage in the Critically IllKeratitisNCT00513734Barts & The London NHS Trust40
已完成
3 期
A Single Centre Study to Compare the Efficacy and Safety of Femtosecond Laser-Assisted Versus Manual Cataract SurgeryCataractNCT01373853Technolas Perfect Vision GmbH131